

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 April 2003 (17.04.2003)

PCT

(10) International Publication Number  
**WO 03/030707 A2**


- (51) International Patent Classification<sup>7</sup>: **A61B**
- (21) International Application Number: **PCT/IT02/00629**
- (22) International Filing Date: 3 October 2002 (03.10.2002)
- (25) Filing Language: **Italian**
- (26) Publication Language: **English**
- (30) Priority Data:  
FI2001A000181 5 October 2001 (05.10.2001) **IT**
- (71) Applicant (*for all designated States except US*): **FLYBY S.R.L.** [IT/IT]; Via Molise, 24, I-57124 Livorno (IT).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **SIMEONE, Emilio** [IT/IT]; Via Molise, 24, I-57124 Livorno (IT).
- (74) Agent: **NESTI, Antonio**; Bugnion S.p.A., Viale Lancetti, 17, I-20158 Milano (IT).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **METHOD AND DEVICE FOR DETERMINING THE MINIMUM ERYTHEMATOUS AMOUNT RELATING TO HUMAN SKIN EXPOSURE TO ULTRAVIOLET RADIATION**



(57) Abstract: A method of determining the minimal erythral dose (MED) on exposing the skin of a subject to UV radiation, comprising the following steps: irradiating at least one region (P2) of any kind of the body skin of a subject (S) with at least two radiations, each in a different spectral band (a, b), at least one of which is correlatable only or mainly with the melanin amount present in the skin; carrying out the reflectance (or absorbance) measurement relating to said bands at said irradiation point; calculating the value of the minimal erythral dose (MED) as a function of the measurements carried out. And a device for putting the method into practice.

METHOD AND DEVICE FOR DETERMINING THE MINIMUM  
ERYTHEMATOUS AMOUNT RELATING TO HUMAN SKIN EXPOSURE TO  
ULTRAVIOLET RADIATION

5                                   D e s c r i p t i o n

Technical Field

10       The invention falls within the field of the methods and  
apparatus used for measurement and control of the amount  
of UV radiation in relation to the photodermatologic  
effects of the human skin. In more detail, the invention  
relates to a method and a device to be used in the field  
concerning treatments by UV radiation for therapeutical  
15       and aesthetic purposes, in order to determine the minimum  
erythematous amount, in the following referred to as MED  
(Minimal Erythemal Dose).

Prior Art

20       At the present state of the art, for determining the MED  
for a given skin region of a person, the method which is  
mostly used is that of photo tests: a controlled  
irradiation of increasing doses of UV rays is carried out  
25       so as to evaluate the different skin reactions. Also  
known in the scientific literature are methods  
correlating the MED with data acquired through a specific  
questionnaire, typically by defining different classes of  
skin types (phototypes).

30       Other methods use the reflectance measurement, defined as  
the electromagnetic radiation fraction incident on the  
skin surface reflected by diffusion from the skin itself  
(it is therefore the fraction that is not reflected in  
35       mirror image relationship from the surface), bound to the  
amount of melanin present in the patient's skin.

However, the known methods and apparatus do not solve the problem of a fully reliable characterization of the MED value in a patient, both due to the great variability of this value for the same phototype and in particular due to the fact that until now it was not possible to individually consider the contribution of the natural constitutive photo protection of a skin that has not been previously irradiated and the contribution relating to an optional photo protection, i.e. induced by previous exposures such as for example afflux to the surface and/or production of melanin and increase in the skin thickness.

#### Object

A first object of the method and the device of the invention is therefore to enable a reliable and careful determination of the MED of any skin region in any subject or patient, in the real skin conditions of this subject at a given instant, capable of solving the drawbacks bound to use of traditional methods and apparatus.

#### Summary of the Invention

To this aim, in accordance with the invention, a method of determining the MED has been devised which comprises a set of at least two reflectance measurements, each relating to a different spectral band within the range of the visible light and the near infrared light (VIS/NIR) of the electromagnetic spectrum, at least one of which is correlated with the amount of melanin present in the skin. This set of measurements must be carried out at least in the skin portion of which the MED is wished to be determined, generally depending both on the optional pigmentation and skin thickening, resulting from possible

preceding exposures.

The measurement is preferably also carried out at a second skin region that can be taken as reference portion because it can be considered as never exposed to UV radiation, i.e. in which the skin pigmentation and thickness can be assumed as exclusively dependent on the constitutive photo protective features of the subject and not affected by previous exposures to UV radiation.

10

The MED is therefore calculated based on the at least two reflectance values obtained (four values in the preferred case).

15 The invention further relates to a device for putting the method into effect, comprising a spectrophotometer for at least the two reflectance measurements or other magnitudes directly correlatable therewith (e.g. absorbance), and a calculating unit and possibly a data  
20 storing unit, interfaced and/or integrated with said spectrophotometer for calculation of the corresponding MED.

The obtained advantages essentially consist in  
25 reliability, efficiency and high personalisation in determining the MED. Personalization is due in particular to the fact that the set of measurements carried out on the reference portion of the patient's skin (the skin portion that can be assumed as previously not exposed to  
30 UV radiation) is associated with the constitutive skin features, whereas the set of measurements carried out in the other portion takes into account the current conditions of the skin itself in the real exposure conditions (e.g. optional photo protection).

35

Brief Description of the Drawings

The foregoing and further advantages will be better understood by a person of ordinary skill in the art from the following description and the accompanying drawings, given by way of non-limiting example, in which:

- 5 - Fig. 1 shows the graph of a possible course of the MED in accordance with the method of the invention for different phototypes;
- Fig. 2 shows a table of the phototypes traditionally used in accordance with DIN-5050 standards;
- 10 - Fig. 3 shows the absorption spectra of some typical substances present in the human skin and the band selection criterion for the reflectance (absorbance) measurements;
- Fig. 4 diagrammatically shows accomplishment of a method of an aesthetic treatment in accordance with the invention on a patient in a first UV-exposure session;
- 15 - Fig. 5 diagrammatically shows accomplishment of the method in Fig. 4 in a UV-exposure session following the first one;
- 20 - Fig. 6 diagrammatically shows a device in accordance with the invention.

#### Description of the method

- 25 In a preferred embodiment, the method of determining the minimal erythemal dose, MED, in accordance with the invention contemplates carrying out, at different points P1, P1', P2 of the body of a subject S, at least two reflectance (or absorbance) measurements, each relating
- 30 to a different spectral band within the spectral range of the visible and near infrared (between 400 and 1400 nm) electromagnetic spectrum (VIS/NIR), of which at least one is only or mainly correlatable with the amount of melanin present in the skin.

35

This means that for this band, absorption due to melanin

can be considered as prevalent with respect to other causes such as haemoglobin or beta-carotene for example (see Fig. 3 in the neighbourhood of 660 nm).

- 5 To calculate the MED, at least one first point P1 and/or P1' is considered in a skin portion (gluteus or under-axilla region, for example) that is deemed to have never been previously exposed to UV radiation so as to give an indication of the patient's constitutive photo protection
- 10 (see Fig. 4); as well a second point P2 of a skin portion, a point that, for example, can be judged the maximum exposure point of the patient for the concerned exposure conditions (taking into account the skin/UV relative source position, for example, and the spatial
- 15 emission features of the UV source, be it an artificial or a natural source), in which the photo protection features also depend on the reactions induced by possible previous exposures to UV rays.
- 20 For measurement, preferably a spectrophotometer is used which is capable of measuring the reflectance ( $R_\lambda$ ) relating to different spectral bands each characterized by a different wavelength  $\lambda$ , or equivalently the absorbance ( $A_\lambda = 100 \log_{10} (1/R_\lambda)$ ) or logarithm of the
- 25 inverse of the reflectance ( $LIR_\lambda = \log_{10} (1/R_\lambda)$ ), such as in the case of the spectrophotometer produced by Diastron Limited (GB).

On defining the following parameters, reference being

30 made for expository convenience to the case of a set of measurements limited to two spectral bands alone, " $\alpha$ " and " $\beta$ ", at all events belonging to the spectral range VIS/NIR identified as:

$R_{\alpha,1}$  reflectance measurement in the spectral band  $\alpha$ , for

35 point P1 and/or P1'

$R_{\beta,1}$  reflectance measurement in the spectral band  $\beta$ , for

point P1 and/or P1'

$R_{\alpha,2}$  reflectance measurement in the spectral band  $\alpha$ , for point P2

$R_{\beta,1}$  reflectance measurement in the spectral band  $\beta$ , for  
5 point P2

the following algorithm is followed:

1) Calculation of absorbances from reflectances R (e.g.  $A = \text{Log}_{10} (1/R)$ )

2) Linear combination (LinC) of absorbances A relating to  
10 the set of spectral measurements for each skin point  $P_i$  taken into account that, in the case of two spectral bands alone  $\alpha$  and  $\beta$ , is:

$$\text{LinC} = k_{\alpha,1} \cdot A_{\alpha,1} + k_{\beta,1} \cdot A_{\beta,1} + k_{\alpha,2} \cdot A_{\alpha,2} + k_{\beta,2} \cdot A_{\beta,2} + k$$

wherein  $A_{\lambda,n}$  is the absorbance measured at point n for the  
15 wavelength band  $\lambda$ , and the values of the real constants  $k_{\lambda,1}$  depend on the particular spectral bands therein utilized. If the reference point or points of type 1 are not used, the coefficients of type  $k_{\lambda,1}$  and  $A_{\lambda,1}$  are absent.

20 Should several points of type 1 (e.g. P1 and P2) be present for each spectral band  $\lambda$ , the average or minimum value of the absorbances obtained for the different points is considered.

3) Polynomial relation between the MED value relating to  
25 point P2 and the linear combination obtained (LinC) :  
[Eq. 1)

$$\text{MED}_{P2} = \text{poly} (\text{LinC})$$

wherein the degree and value of the polynomial coefficients can be different depending on the considered  
30 spectral bands.

It is understood that the relation between MED and LinC can be expressed following any statistical correlation method, for example a neural network calibrated on the  
35 basis of a record of cases of LinC/MED values.

In an example for putting the method into practice, reflectance measurements for the spectral bands relating to the green light (568 nm) and the red light (655 nm) have been utilised. In the last-mentioned band melanin absorption is in fact high, whereas absorption due to other substances, such as haemoglobin, can be considered as negligible. In the current example therefore the absorbance in the red light  $A_{red}$  and that relating to the green light  $A_{green}$  are taken into account for point P1 and point P2. Shown in Fig. 3 is the distribution of a number of MED measurements (expressed in effective erythema  $J/m^2$ ) for different patients, carried out by photo test (circular points) and of the corresponding MED values provided in accordance with the exposed method (square points).

In this application, the formula Eq. [1] has shown a correlation coefficient greater than 0.85 and a mean error of about 10% with respect to the MED value obtained from the photo test.

Preferably, also introduced into the relation Eq. [1] is a parameter  $K_{anam}$  which is drawn from the patient's photodermatologic anamnesis and which enables the correlation of the found relation to be further improved.

In accordance with the invention, the described method finds a particularly advantageous use in the field of cosmetic and possibly therapeutical treatments applied to a subject, which are based on UV radiation. In this case, the method comprises a further step of irradiating the patient with a controlled dose of UV rays lower than or equal to the MED calculated with the above described method, supposing that the patient does not suffer from pathologies, has not taken photosensitizing substances and did not expose himself/herself to UV radiation out of



the treatment. Preferably also provided is a step of recording the data of a patient who is destined to a subsequent exposure session.

- 5 In particular, for a patient who is submitted to a UV radiation for the first time, the method preferably contemplates the following steps (Fig. 4):
- a) initializing a personalized file for the patient, DB;
  - b) carrying out a photodermatologic anamnesis of the  
10 patient and assigning a corresponding value of the parameter  $K_{anam}$  and/or a first estimate of the MED ( $MED_{anam}$ ), and recording the data to DB;
  - c) executing the set of the reflectance (absorbance) measurements at a point P2 of a patient's skin portion  
15 that can be considered as a portion of maximum exposure based on the patient's irradiation conditions depending on the features of irradiance and geometry of the UV source utilized and the patient's arrangement relative thereto;
  - 20 d) possibly, carrying out the set of reflectance (absorbance) measurements at least at one point P1, P1' of a skin portion that substantially has never been exposed to a UV radiation;
  - e) calculating the MED by the described method, based on  
25 the data drawn from the previous steps b), c) and possibly d).
- When determination of the MED has been carried out, the patient can be irradiated, except for regions of type 1 (P1 and P1') with a smaller dose than the MED without  
30 causing erythema.
- f) updating file DB with at least the data relating to step d) if carried out, and the data of the dose and date and hour of the possible UV administration.

- 35 In the sessions following the first one the method contemplates the steps of (Fig. 5):

- c') repeating the procedure described in the preceding step c);  
e') calculating the MED based on the data in DB and from step c');  
5 Based on the time gap elapsed from the last administration the patient may possibly be enabled to be irradiated with a lower UV dose than the determined new MED value.  
f) updating file DB with at least the date and hour of  
10 the possible new administration of UV dose.

Preferably, steps e), e') contemplate calculation of the MED based on the method described in the preceding paragraph.

15

Description of the Apparatus for Determination of the MED

The invention also relates to a device for carrying out the set of two or more reflectance (absorbance)  
20 measurements in accordance with the described method and outputting the value of the calculate MED.

With reference to Fig. 6, the device comprises a spectrophotometric unit 1 capable of being brought into  
25 side by side relationship with one or more points P1, P1', P2 of the patient's skin for the reflectance measurements and a connection 2 for transmission of the measured data to a processing unit 3 and possible storage 4 thereinto. Units 1, 2, 3 and possibly 4 can be  
30 also integrated into a single device. Preferably units 3 and 4 are a single microprocessing unit calculating the MED based on the described algorithm.

Preferably the device comprises a display 5 for showing  
35 data concerning the patient, such as MED, skin reflectances on two or more spectral bands, and indirect

data such as melanin index, erythemic exposure time  $t_{MED}$  for a source of known effective erythemal UV irradiance  $Irr_{UV}$ , ...).

5 In addition to the measurement data relating to the patient, the data storage may also contemplate the effective erythemal UV irradiance data  $Irr_{UV}$  relating to one or more UV sources, on the basis of which the minimal erythemal exposure time  $t_{MED}$  is calculated:

10  $t_{MED} = MED / Irr_{UV}$  (Eq. 2)

) in which the appropriate measurement units are utilized (e.g.  $[MED] = J/m^2$ ,  $[Irr_{UV}] = W/n^2$ ,  $[t_{MED}] = s$ ).

The present invention has been described with reference  
15 to preferred embodiments but it is understood that equivalent modifications can be made by a person skilled in the art without departing from the protective scope of the appended claims.

)

C L A I M S

1. A method of determining the minimal erythema dose (MED) in exposing the skin of a subject to UV radiation, comprising the following steps:
- irradiating at least one region (P2) of the body skin of a subject or patient (S) generally characterized by both constitutive and optional photo protection with at least two radiations, each in a different spectral band (a, b) within the spectral range of the electromagnetic visible and near infrared spectrum approximately between 400 and 1400 nm (VIS/NIR), at least one of said radiations being only or mainly correlatable with the melanin amount present in the skin;
  - carrying out the measurement of the reflectance (absorbance) relating to said bands at said irradiation point;
  - calculating the value of the minimal erythema dose (MED) at (P2) as a function of the carried out reflectance measurements (R).
2. A method as claimed in claim 1, wherein in addition to the reflectance measurements relating to point (P2), also considered are the reflectance values according to steps a and b on one or more skin regions of the patient (P1, P1') that normally have never been exposed to UV radiation, in which pigmentation can be supposed to be exclusively of the constitutive type.
3. A method as claimed in claim 1 or 2, wherein said (MED) is calculated in the form of a polynomial relation  $MED = \text{poly}(\text{LinC})$  (Eq. [1]),
- $$\text{LinC} = k_{a,1} \cdot A_{a,1} + k_{b,1} \cdot A_{b,1} + k_{a,2} \cdot A_{a,2} + k_{b,2} \cdot A_{b,2} + k$$
- wherein  $(a_i, j)$  is the absorbance measured at points  $P_j$  (P1,2) for the frequency band  $i$  (a, b), and  $(k, k_{ij})$  are real constants depending on the at least spectral bands

- 12 -

(a, b) that have been utilized.

4. A method as claimed in claim 3, wherein in the case of several points of type (P1, P1') for each spectral band  $\lambda$ , the average or the minimum one of the values of the absorbances obtained for the different points is considered.

5. A method as claimed in claim 1, wherein said reflectance measurements are carried out in the spectral bands relating to the green light (e.g. wavelength 568 nm) and the red light (e.g. wavelength 655 nm).

6. A method as claimed in one or more of the preceding claims wherein at least one of said reflectance measurements is correlated with the haemoglobin amount present in the irradiated region of the patient's skin.

7. A method of treating a patient through UV radiation, comprising the following steps:

- carrying out the reflectance (absorbance) measurements at a point (P2) of a patient's skin portion that can be considered as a portion of maximum exposure based on the patient's irradiation conditions depending on the features of irradiance and geometry of the UV source utilized and the patient's arrangement relative thereto;
- calculating the MED based on the data drawn from the preceding steps and exposing the patient to UV irradiation, except for the regions (P1 and P1'), in a dose lower than or equal to the MED.

8. A method as claimed in claim 7, wherein in said step of measuring the reflectance, also reflectance (absorbance) measurements are carried out at least at one point (P1, P1') of the patient's skin that substantially has never been exposed to a UV radiation.

9. A method as claimed in claim 7 or 8, wherein a preliminary step is included which involves initialization of a personalized file (DB) for the patient.

5

10. A method as claimed in claim 8 or 9, wherein a step of updating file DB with at least the measurement data on said points (P1, P1') is included.

10 11. A method as claimed in claim 9 or 10, wherein a step is included which consists in carrying out a photodermatologic anamnesis of the patient and assigning a corresponding value of the parameter  $K_{anam}$  and/or a first estimate of the MED ( $MED_{anam}$ ), and recording the  
15 data to file DB.

12. A method as claimed in claim 9, wherein several treatment sessions are provided and wherein in sessions subsequent to the first one provision is made for the  
20 steps of calculating the MED based on data in (DB) and the step of calculating the MED and updating file DB with at least the date and hour of the possible new UV dose administration.

25 13. A method as claimed in one or more of claims 7 to 12, wherein the steps of calculating the MED are carried out based on the method as claimed in claims 1-6.

14. A method as claimed in claim 12, comprising a step of  
30 controlling the time gap elapsed from the last administration based on which the subject can possibly be enabled to be irradiated with a lower UV dose than the determined new MED value.

35 15. A device for calculating the MED for a subject submitted to UV radiation, characterized in that it

comprises:

- a spectrophotometric unit (1) of at least two spectral bands (a, b), capable of being brought into side by side relationship with one or more points (P1, P1', P2) of the patient's skin for the reflectance measurements;
- a connection (2) for measurement transmission to a data processing unit (3) for calculating the (MED) and other magnitudes (e.g. minimal erythema exposure time) based on measurement data received from said unit (1);
- a memory (4) for inputting to a file (DB) and updating the personal measurement data of one or more patients from a spectrophotometer (1) and the features of one or more UV sources (e.g. UV irradiance) to be used for administration of the dose, wherein said processing unit (3) comprises means for calculating the MED according to one or more of claims 1-6.

16. A device as claimed in claim 15, wherein the units (1, 2, 3 and 4) are integrated into a single body.

17. A device as claimed in claim 15, wherein the units (3) and (4) are integrated into a single microprocessing unit with memory, provided with means for calculating the MED and possibly other magnitudes derived from the measurements and/or parameters stored therein such as melanin index, minimal erythema exposure time for a given source of a stored or assigned effective erythema UV irradiance  $Irr_{UV}$ :  $t_{MED} = MED / Irr_{UV}$  (eq. 2).

18. A device as claimed in claim 15, comprising a display (5) showing the data relating to the patient, as well as the calculated magnitudes.

19. An apparatus for administration of UV doses to a subject comprising:

- a device for measurement of the MED according to at

least one of claims 15-18;

- at least one UV source for controlled administration of a dose not exceeding the MED calculated for the subject.






FIGURE 1

| Phototype | Tan       | Burn      | Hair  | Eyes       | MED<br>(J/m <sup>2</sup> ) |
|-----------|-----------|-----------|-------|------------|----------------------------|
| I         | never     | always    | red   | blue       | 200                        |
| II        | sometimes | sometimes | fair  | blue/green | 250                        |
| III       | always    | seldom    | brown | grey/brown | 350                        |
| IV        | always    | never     | black | brown      | 450                        |

FIGURE 2




FIGURE 3

4/6




FIGURE 4





FIGURE 5



1: Spectrophotometer having at least two spectral bands

2: Connecting means for transmission to data processing unit

3: Processing unit

4: Data storage and parameters

5: Display (e.g. MED value, reflectance and other associated values such as exposure time associated with UV source)

FIGURE 6

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 April 2003 (17.04.2003)

PCT

(10) International Publication Number  
WO 03/030707 A3

(51) International Patent Classification<sup>7</sup>: A61B 5/103, 5/00

(21) International Application Number: PCT/IT02/00629

(22) International Filing Date: 3 October 2002 (03.10.2002)

(25) Filing Language: Italian

(26) Publication Language: English

(30) Priority Data:  
FI2001A000181 5 October 2001 (05.10.2001) IT

(71) Applicant (for all designated States except US): FLYBY S.R.L. [IT/IT]; Via Molise, 24, I-57124 Livorno (IT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): SIMEONE, Emilio [IT/IT]; Via Molise, 24, I-57124 Livorno (IT).

(74) Agent: NESTI, Antonio; Bugnion S.p.A., Via Goito, 18, I-40126 Milano (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

(88) Date of publication of the international search report:  
2 October 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD AND DEVICE FOR DETERMINING THE MINIMUM ERYTHEMAL DOSE



(57) Abstract: A method of determining the minimal erythral dose (MED) on exposing the skin of a subject to UV radiation, comprising the following steps: irradiating at least one region (P2) of any kind of the body skin of a subject (S) with at least two radiations, each in a different spectral band (a, b), at least one of which is correlatable only or mainly with the melanin amount present in the skin; carrying out the reflectance (or absorbance) measurement relating to said bands at said irradiation point; calculating the value of the minimal erythral dose (MED) as a function of the measurements carried out. And a device for putting the method into practice.

WO 03/030707 A3

## INTERNATIONAL SEARCH REPORT

Intern      ilication No

PC1/PT UZ/00629

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7    A61B5/103    A61B5/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7    A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data-base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| X          | WO 93 16635 A (CHROMO LIGHT APS)<br>2 September 1993 (1993-09-02)<br>page 10, line 9 -page 15, line 29; claims<br>1-10; figures 4,5 | 1,2,5,6,<br>15-19     |
| X          | US 4 882 598 A (WULF HANS C)<br>21 November 1989 (1989-11-21)<br>column 3, line 1 -column 5, line 40                                | 1,2                   |
| X          | US 5 636 637 A (DE RIGAL JEAN ET AL)<br>10 June 1997 (1997-06-10)<br>column 7, line 33 -column 8, line 27                           | 1                     |
| A          | US 4 423 736 A (DEWITT DAVID P ET AL)<br>3 January 1984 (1984-01-03)<br>the whole document  | 1,15,19               |
|            | -/--  |                       |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*S\* document member of the same patent family

Date of the actual completion of the international search

18 February 2003

Date of mailing of the international search report

19/03/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Petter, E



## INTERNATIONAL SEARCH REPORT

Intern

Publication No

PC1/IT 02/00629

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| A          | DE 297 22 723 U (MENZEL EBERHARD PROF DR<br>;SIPPEL RUEDIGER (DE))<br>22 April 1999 (1999-04-22)<br>the whole document   | 1,15                  |
| A          | KRUTMANN J; HÖNIGSMANN H.: "Handbuch der<br>dermatologischen Phototherapie und<br>Photodiagnostik"<br>1997, SPRINGER VERLAG, BERLIN<br>XP002231586<br>page 314 -page 315<br>page 362 -page 367   | 1,15,19               |
| A          | SCHMIDT W-D ET AL: "NON-CONTACTING<br>DIFFUSE VIS-NIR SPECTROSCOPY OF HUMAN SKIN<br>FOR EVALUATION OF SKIN TYPE AND<br>TIME-DEPENDENT MICROCIRCULATION"<br>PROCEEDINGS OF THE SPIE, SPIE, BELLINGHAM,<br>VA, US,<br>vol. 4160, 6 July 2000 (2000-07-06), pages<br>91-102, XP008008978<br>the whole document      | 1,15,19               |
| A          | FEATHER J W ET AL: "A portable<br>reflectometer for the rapid quantification<br>of cutaneous haemoglobin and melanin".<br>PHYSICS IN MEDICINE AND BIOLOGY, TAYLOR<br>AND FRANCIS LTD. LONDON, GB,<br>vol. 33, no. 6, June 1988 (1988-06), pages<br>711-722, XP002186027<br>ISSN: 0031-9155<br>the whole document | 1,15,19               |
| P,X        | EP 1 170 035 A (KONINKL PHILIPS<br>ELECTRONICS NV)<br>9 January 2002 (2002-01-09)<br>the whole document  | 1,15-19               |
| P,X        | US 6 452 188 B1 (CHUBB CHARLES R)<br>17 September 2002 (2002-09-17)<br>column 8, line 66 -column 10, line 34   | 1                     |

# INTERNATIONAL SEARCH REPORT

Int al application No.  
PCT/IT 02/00629

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 7-14  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Inter - Application No

PC1/11 02/00629

| Patent document<br>cited in search report |    | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|----|---------------------|----------------------------|---------------------|
| WO 9316635                                | A  | 02-09-1993          | DE 69319585 D1             | 13-08-1998          |
|   |    |                     | DE 69319585 T2             | 15-04-1999          |
|   |    |                     | WO 9316635 A1              | 02-09-1993          |
|   |    |                     | EP 0629124 A1              | 21-12-1994          |
| US 4882598                                | A  | 21-11-1989          | AT 109668 T                | 15-08-1994          |
|   |    |                     | DE 3650024 D1              | 15-09-1994          |
|   |    |                     | DE 238574 T1               | 30-06-1988          |
|   |    |                     | DK 269887 A                | 25-05-1987          |
|   |    |                     | WO 8701948 A1              | 09-04-1987          |
|   |    |                     | EP 0238574 A1              | 30-09-1987          |
|   |    |                     | NO 872211 A                | 27-07-1987          |
| US 5636637                                | A  | 10-06-1997          | FR 2719989 A1              | 24-11-1995          |
|   |    |                     | AU 684003 B2               | 27-11-1997          |
|   |    |                     | AU 2005295 A               | 30-11-1995          |
|   |    |                     | CA 2149600 A1              | 21-11-1995          |
|   |    |                     | EP 1183995 A2              | 06-03-2002          |
|   |    |                     | EP 1264578 A2              | 11-12-2002          |
|   |    |                     | EP 0682912 A1              | 22-11-1995          |
|   |    |                     | JP 3269750 B2              | 02-04-2002          |
|   |    |                     | JP 7313468 A               | 05-12-1995          |
| US 4423736                                | A  | 03-01-1984          | NONE                       |                     |
| DE 29722723                               | U  | 22-04-1999          | DE 29722723 U1             | 22-04-1999          |
| EP 1170035                                | A  | 09-01-2002          | EP 1170035 A2              | 09-01-2002          |
|   |    |                     | US 2002022868 A1           | 21-02-2002          |
| US 6452188                                | B1 | 17-09-2002          | NONE                       |                     |

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**